

**ALKEM LABORATORIES LTD.****Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,

Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955

• Email: contact@alkem.com • Website: www.alkemlabs.com

• CIN: L00305MH1973PLC174201

09th August, 2024

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. Scrip Symbol: ALKEM
---	--

Sub: Outcome of Board Meeting held on 09th August, 2024

Dear Sir(s)/ Madam,

This is with reference to our earlier intimation dated 25th July, 2024, pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), regarding holding of Board Meeting on 09th August, 2024 to *inter alia* approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2024. The Board of Directors at its meeting held today, i.e. 09th August, 2024 has, *inter alia*:

1. approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2024.

A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the SEBI LODR Regulations, is enclosed herewith.

2. based on recommendation of Nomination and Remuneration Committee and subject to approval of shareholders, approved the appointment of Mr. Rajeev Kher (DIN: 01192524) as an Additional Director designated as an Independent Director on the Board of Directors of the Company for a term of 5 (five) consecutive years w.e.f. 09th August, 2024 upto 08th August, 2029.

The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 01.00 p.m.

Kindly take the same on record.

Sincerely,

For **Alkem Laboratories Limited**


Manish Narang
President - Legal, Company Secretary & Compliance Officer

Encl.: a/a

Limited Review Report on unaudited consolidated financial results of Alkem Laboratories Limited for the quarter ended 30 June 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**To the Board of Directors of Alkem Laboratories Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alkem Laboratories Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2024 ("the Statement"), (in which are included financial information from one branch) being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2024 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditor referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Limited Review Report (Continued)

Alkem Laboratories Limited

7. We did not review the interim financial results of 2 Subsidiaries included in the Statement, whose interim financial results reflects total revenues (before consolidation adjustments) of Rs. 2,499 million, total net profit after tax (before consolidation adjustments) of Rs. 115 million and total comprehensive income (before consolidation adjustments) of Rs. 108 million, for the quarter ended 30 June 2024, as considered in the Statement. These interim financial results have been reviewed by other auditor whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Sreeja Marar

Partner

Mumbai

09 August 2024

Membership No.: 111410

UDIN:24111410BKGQOU1349

Limited Review Report (Continued)

Alkem Laboratories Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Alkem Laboratories Limited	Parent
2	S&B Holdings S.a.r.l, (Previously known as S&B Holding B.V with principle place of buisness based at Netherlands redomiciled to Luxembourg w.e.f 16 Oct 2023)	Wholly Owned Subsidiary
3	The Pharma Network LLC, USA (TPN)	Wholly Owned Subsidiary
4	Ascend Laboratories LLC, USA	Wholly Owned Subsidiary of TPN
5	S & B Pharma LLC	Wholly Owned Subsidiary of TPN
6	Pharmacor Pty Limited, Australia	Wholly Owned Subsidiary
7	Enzene Biosciences Ltd, India	Subsidiary
8	Ascend Laboratories (PTY) Ltd, South Africa	Wholly Owned Subsidiary
9	Cachet Pharmaceuticals Pvt Ltd, India	Subsidiary
10	Indchemie Health Specialities Pvt Ltd , India	Subsidiary
11	Alkem Laboratories Corporation, Philippines	Wholly Owned Subsidiary
12	Ascend GmbH, Germany	Wholly Owned Subsidiary
13	Ascend Laboratories SDN BHD., Malaysia	Wholly Owned Subsidiary
14	Ascend Laboratories SpA Chile (Ascend Chile)	Wholly Owned Subsidiary

ARW

Limited Review Report (Continued)**Alkem Laboratories Limited**

15	Pharma Network SpA, Chile	Wholly Owned Subsidiary of Ascend Chile
16	Ascend Laboratories S.A. DE C.V., Mexico	Wholly Owned Subsidiary of Ascend Chile
17	Alkem Laboratories Korea Inc, Korea	Wholly Owned Subsidiary
18	Pharmacor Ltd , Kenya	Wholly Owned Subsidiary
19	The Pharma Network LLP, Kazakhstan	Wholly Owned Subsidiary
20	Ascend Laboratories (UK) Ltd, UK	Wholly Owned Subsidiary
21	Ascend Laboratories Ltd, Canada	Wholly Owned Subsidiary
22	Alkem Foundation. India	Wholly Owned Subsidiary
23	Connect 2 Clinic Private Limited, India	Wholly Owned Subsidiary
24	Ascend Laboratories SAS, Colombia	Wholly Owned Subsidiary
25	Pharmacor Limited, New Zealand	Wholly Owned Subsidiary of Pharmacor Limited, Australia
26	Enzene Inc., USA	Wholly Owned Subsidiary of Enzene Biosciences Ltd, India
27	Alkem Medtech Private Limited, India (incorporated on 27 March 2024)	Wholly Owned Subsidiary

SKM

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Unaudited Consolidated Financial Results for the Quarter ended 30 June 2024

(₹ In Million except per share data)


Particulars	Quarter ended			Year ended
	30.06.2024 Unaudited	31.03.2024 (Refer Note 2)	30.06.2023 Unaudited	31.03.2024 Audited
1 Income				
(a) Revenue from Operations	30,318.2	29,358.2	29,677.2	126,675.8
(b) Other Income	1,203.1	881.7	658.4	3,108.4
Total Income	31,521.3	30,239.9	30,335.6	129,784.2
2 Expenses				
(a) Cost of materials consumed	8,371.6	7,987.6	8,325.8	32,945.9
(b) Purchases of stock-in-trade	3,826.6	3,807.0	3,554.7	16,288.7
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,438.7)	(720.6)	105.2	141.2
(d) Employee benefits expense	6,022.7	5,058.3	5,676.5	22,010.1
(e) Finance costs	291.1	268.6	297.7	1,124.1
(f) Depreciation and amortisation expense	804.8	834.3	724.1	2,993.0
(g) Other expenses	7,449.6	9,206.1	8,123.1	32,835.0
Total Expenses	25,327.7	26,441.3	26,807.1	108,338.0
3 Profit before exceptional items and tax (1) - (2)	6,193.6	3,798.6	3,528.5	21,446.2
4 Exceptional items (refer note 3)	-	(125.2)	-	(1,214.9)
5 Profit before tax (3) + (4)	6,193.6	3,673.4	3,528.5	20,231.3
6 Tax expense / (credit)				
(a) Current tax	1,244.3	838.5	657.8	4,222.8
(b) Deferred tax	(553.1)	(209.9)	(7.4)	(2,106.1)
Total Tax Expense (a + b)	691.2	628.6	650.4	2,116.7
7 Profit for the period (5) - (6)	5,502.4	3,044.8	2,878.1	18,114.6
8 Other Comprehensive Income (net of tax)				
(a) (i) Items that will not be reclassified to profit or loss	(49.8)	2.3	(39.5)	(93.4)
(ii) Income tax relating to items that will not be reclassified to profit or loss	16.0	(2.1)	13.1	29.8
(b) (i) Items that will be reclassified to profit or loss	74.9	(76.7)	138.6	264.0
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Total Other Comprehensive Income/Loss (net of tax)	41.1	(76.5)	112.2	200.4
9 Total Comprehensive Income for the period (7) + (8)	5,543.5	2,968.3	2,990.3	18,315.0
10 Profit attributable to				
a) Owners of the Company	5,451.6	2,935.6	2,867.3	17,957.7
b) Non-Controlling Interest	50.8	109.2	10.8	156.9
11 Other Comprehensive Income attributable to				
a) Owners of the Company	44.1	(76.8)	116.9	206.5
b) Non-Controlling Interest	(3.0)	0.3	(4.7)	(6.1)
12 Total Comprehensive Income attributable to				
a) Owners of the Company	5,495.7	2,858.8	2,984.2	18,164.2
b) Non-Controlling Interest	47.8	109.5	6.1	150.8
13 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1
14 Other Equity				102,881.5
15 Earnings Per Share (not annualised for the quarters)				
(a) Basic (₹)	45.60	24.55	23.98	150.19
(b) Diluted (₹)	45.60	24.55	23.98	150.19

Notes to the Consolidated Financial results:

- 1 The above unaudited consolidated financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The Consolidated Financial results are prepared in accordance with Ind AS 110 'Consolidated Financial Statements'.
- 2 The above unaudited consolidated financial results of the Company were reviewed and recommended by the Audit Committee on 08 August 2024 and subsequently approved by the Board of Directors at its meeting held on 09 August 2024. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2024. The figures for the quarter ended 31 March 2024 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to 31 December 2023, which were subjected to limited review.
- 3 a. Consequent to changes in market dynamics and assessment of recoverable value where indicators of impairment were identified, the group has recognized an impairment loss of:
 - ₹ 415.6 Million in respect of its plant located at Indore during the previous quarter and year ended 31 March 2024
 - ₹ 576.6 Million in respect to the plant located at St. Louis, USA, a unit under S&B Pharma LLC, a subsidiary of the Company in the previous year ended 31 March 2024.These amounts are reflected under 'Exceptional Items' in the respective periods.
- b. During the year ended 31 March 2024, a Cyber security incident which compromised business email IDs of certain employees at one of the Group's subsidiaries, resulted in a fraudulent transfer of ₹ 513.1 Million of which the Group has recovered an amount of ₹ 290.4 Million in quarter ended 31 March 2024 resulting in a net amount of ₹ 222.7 Million shown as 'Exceptional items' in the Statement of Profit and Loss for the year ended 31 March 2024.
- 4 The Group operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment has been made.

Place: Mumbai
Date: 09 August 2024

By Order of the Board
For Alkem Laboratories Limited



B.N. Singh
Executive Chairman
DIN: 00760310

Limited Review Report on unaudited standalone financial results of Alkem Laboratories Limited for the quarter ended 30 June 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Alkem Laboratories Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2024 ("the Statement"), which includes financial information of one branch.
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2024 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it

SRM

B S R & Co. LLP

Limited Review Report (Continued)
Alkem Laboratories Limited

contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248WW-100022



Sreeja Marar

Partner

Mumbai

09 August 2024

Membership No.: 111410

UDIN:24111410BKGQOT4044

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Unaudited Standalone Financial Results for the Quarter ended 30 June 2024

(₹ In Million except per share data)

Particulars	Quarter ended			Year ended
	30.06.2024 Unaudited	31.03.2024 (Refer note 2)	30.06.2023 Unaudited	31.03.2024 Audited
1 Income				
(a) Revenue from Operations	25,001.0	23,653.7	22,531.7	97,477.2
(b) Other Income	1,061.0	837.9	647.0	3,059.9
Total Income	26,062.0	24,491.6	23,178.7	100,537.1
2 Expenses				
(a) Cost of materials consumed	7,612.3	6,527.1	6,893.7	27,499.3
(b) Purchases of stock-in-trade	2,073.6	2,699.6	2,451.7	11,287.0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(856.6)	86.7	(632.3)	(713.1)
(d) Employee benefits expense	4,259.0	3,434.1	4,140.6	15,602.8
(e) Finance costs	214.4	206.8	214.2	819.1
(f) Depreciation and amortisation expense	643.5	691.0	581.1	2,443.5
(g) Other expenses	5,706.4	6,831.0	6,340.5	24,149.9
Total Expenses	19,652.6	20,476.3	19,989.5	81,088.5
3 Profit before exceptional items and tax (1) - (2)	6,409.4	4,015.3	3,189.2	19,448.6
4 Exceptional Items (refer note 3)	-	(125.2)	-	(638.3)
5 Profit before tax (3) + (4)	6,409.4	3,890.1	3,189.2	18,810.3
6 Tax expense / (credit)				
(a) Current tax	1,112.6	774.1	539.3	3,332.8
(b) Deferred tax	(535.7)	(133.7)	(64.5)	(1,994.0)
Total Tax expense (a + b)	576.9	640.4	474.8	1,338.8
7 Profit for the period after tax (5 - 6)	5,832.5	3,249.7	2,714.4	17,471.5
8 Other Comprehensive Income (net of tax)				
(a) (i) Items that will not be reclassified to profit or loss	(38.2)	5.5	(24.1)	(66.8)
(ii) Income tax relating to items that will not be reclassified to profit or loss	13.4	(2.0)	8.4	23.3
(b) (i) Items that will be reclassified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Total Other Comprehensive Income/Loss (net of tax)	(24.8)	3.5	(15.7)	(43.5)
9 Total Comprehensive Income for the period (7) + (8)	5,807.7	3,253.2	2,698.7	17,428.0
10 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1
11 Other Equity				105,307.0
12 Earnings Per Share (not annualised for the quarters)				
(a) Basic (₹)	48.78	27.18	22.70	146.13
(b) Diluted (₹)	48.78	27.18	22.70	146.13

Notes to the Standalone Financial results:

- 1 The above unaudited standalone financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 08 August 2024 and subsequently approved by the Board of Directors at its meeting held on 09 August 2024. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2024. The figures for the quarter ended 31 March 2024 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended 31 December 2023, which were subjected to limited review.
- 3 a. During the quarter and year ended 31 March 2024, the Company has recognized an impairment loss of ₹ 415.6 Million in respect of its plant located at Indore consequent to changes in market dynamics and assessment of recoverable value which is included in 'Exceptional Items'.
b. During the year ended 31 March 2024, a Cyber security incident which compromised business email IDs of certain employees at one of the Company's subsidiaries, resulted in a fraudulent transfer of ₹ 513.1 Million of which the Company has recovered an amount of ₹ 290.4 Million in quarter ended 31 March 2024 resulting in a net amount of ₹ 222.7 Million shown as 'Exceptional items' in the Statement of Profit and Loss for the year ended 31 March 2024.
- 4 The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment has been made.

By Order of the Board
For Alkem Laboratories Limited



B.N. Singh
Executive Chairman
DIN: 00760310

Place: Mumbai
Date: 09 August 2024